Jove
Visualize
联系我们

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Introduction to Hemostasis01:05

Introduction to Hemostasis

18.3K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
18.3K
Coagulation01:09

Coagulation

12.3K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
12.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

471
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
471
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

682
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
682
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策
  1. 首页
  2. 在心脏外科手术中治疗凝血性出血的前热血素复合缩剂与冷血:fares-ii多中心随机临床试验
  1. 首页
  2. 在心脏外科手术中治疗凝血性出血的前热血素复合缩剂与冷血:fares-ii多中心随机临床试验

相关实验视频

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

9.3K

在心脏外科手术中治疗凝血性出血的前热血素复合缩剂与冷血:FARES-II多中心随机临床试验

Keyvan Karkouti1,2,3, Jeannie L Callum4,5, Justyna Bartoszko1,2,3

  • 1Department of Anesthesia and Pain Management, University Health Network, Sinai Health, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada.

JAMA
|March 29, 2025

在PubMed 上查看摘要

概括
此摘要是机器生成的。

与冷血相比,四因子血栓复合缩剂 (PCC) 在心脏手术患者治疗出血方面表现出更高的血静效率和安全性. 这一发现表明PCC是心脏手术后凝血治疗的更有效的替代方案.

更多相关视频

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.4K

相关实验视频

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
06:23

Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo

Published on: August 4, 2018

9.3K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.4K

科学领域:

  • 心血管外科
  • 血液学
  • 危急护理医学

背景情况:

  • 过度出血是心脏手术后的一个严重并发症.
  • 缺乏凝血因子往往需要冷血治疗.
  • 四因子前激素复合缩剂 (PCC) 是一种潜在的替代疗法.

研究的目的:

  • 为了比较PCC与冷血的疗效和安全性.
  • 评估心脏手术后患有凝血病的成年患者的治疗结果.

主要方法:

  • 一个非盲目的,随机的,非劣势的受控试验.
  • 在北美12家医院的538名成年患者中.
  • 患者在心脏手术后接受PCC或冷血治疗.

主要成果:

  • 与冷血相比,PCC具有更高的静血效果 (77. 9% 与 60. 4% 相比).
  • 接受PCC的患者需要更少的血液产品输血 (平均6. 6对9. 3单位).
  • PCC与较少的严重不良事件和较少的急性损伤有关.

结论:

  • 四因子PCC是一种更有效和更安全的替代品,用于冷血在心脏手术中.
  • 提供显著的止血效益,并减少输血需求.
  • 这些发现支持PCC在心脏手术后治疗出血的使用.